TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8614309

Group type: EXPERIMENTAL
Intervention: Palmvitee (40 mg alpha-tocopherol, 48 mg alpha-tocotrienol, 112 mg gamma-tocotrienol, and 60 mg delta-tocotrienol/day for four weeks)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 200 mg gamma-tocotrienol/day for four weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Dietary regimen alone
Number of subjects: 52

Group type: COMPARATOR
Intervention: Dietary assessments
Number of subjects: 52

Group type: COMPARATOR
Intervention: alpha-Tocopherol
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tocotrienol preparations
Number of subjects: 52

Group type: COMPARATOR
Intervention: Neither preparation
Number of subjects: 52
Study: 2076798

Group type: EXPERIMENTAL
Intervention: Intranasal glucagon (1 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Subcutaneous glucagon (1 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Glycocholic acid (1 mg)
Number of subjects: 18
Study: 7039058

Group type: COMPARATOR
Intervention: Gentamicin (1 mg/kg/iv q8h)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tobramycin (1 mg/kg/iv q8h)
Number of subjects: 36
Study: 30328105

Group type: EXPERIMENTAL
Intervention: Paroxetine (selective serotonin reuptake inhibitor)
Number of subjects: 33
Study: 28655183

Group type: EXPERIMENTAL
Intervention: Internet-delivered therapist-guided cognitive behavior therapy for insomnia
Number of subjects: 43

Group type: COMPARATOR
Intervention: Internet-delivered therapist-guided cognitive behavior therapy for depression
Number of subjects: 43
Study: 24332687

Group type: EXPERIMENTAL
Intervention: Topical anaesthesia with cocaine 4% pledgets
Number of subjects: 92

Group type: COMPARATOR
Intervention: Topical anaesthesia with lidocaine 2% plus 1/100.000 adrenaline pledgets
Number of subjects: 92
Study: 22849337

Group type: EXPERIMENTAL
Intervention: Carvedilol 6.25‐12.5 mg daily
Number of subjects: 121

Group type: COMPARATOR
Intervention: Nadolol 40‐80 mg plus isosorbide‐5‐mononitrate 20 mg daily
Number of subjects: 121
Study: 19726349

Group type: EXPERIMENTAL
Intervention: Parenteral plus enteral nutrition (PN+EN)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 20
Study: 17682411

Group type: EXPERIMENTAL
Intervention: RPCP (Respecting Patient Choices Program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-intervention and control groups
Number of subjects: 0
Study: 16301340

Group type: EXPERIMENTAL
Intervention: Thalidomide (25 mg QD increasing to 200 mg QD)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 12385358

Group type: EXPERIMENTAL
Intervention: Tissue coblation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Bipolar dissection
Number of subjects: 10
Study: 9456273

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 120 mg sustained-release once daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Molsidomine 8 mg sustained-release 3 times daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Molsidomine
Number of subjects: 16
Study: 7887879

Group type: EXPERIMENTAL
Intervention: in vivo exposure plus disconfirmation of misappraisals of bodily sensations
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: in vivo exposure plus relaxation
Number of subjects: 70
Study: 2146996

Group type: EXPERIMENTAL
Intervention: Infusions of third-party donor leucocytes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blocking effect index (BEI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blocking index (BI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulation index (SI)
Number of subjects: 0
Study: 70341

Group type: EXPERIMENTAL
Intervention: Target shocks (1 mA above subjective threshold)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-target shocks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Weaker shocks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Task conditions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Strong shocks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Target shocks
Number of subjects: 12
Study: 31731006

Group type: EXPERIMENTAL
Intervention: Patient navigation (PN) intervention including strengths‐based case management, 1‐1 clinical support, motivational interviewing, and addiction‐relapse prevention programming.
Number of subjects: 0
Study: 30014671

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Hegu (LI 4), Neiguan (PC 6) and Zusanli (ST 36) 20 min before operation; EA combined with regular anesthesia during operation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intramuscular injection of parecoxib sodium (40 mg), combined with regular anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous injection of dezocine (5 mg), combined with regular anesthesia
Number of subjects: 60
Study: 26659833

Group type: EXPERIMENTAL
Intervention: CD133+ cells
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: MNCs
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 24145207

Group type: EXPERIMENTAL
Intervention: Cold pressor test tolerance
Number of subjects: 12981

Group type: COMPARATOR
Intervention: Other experimental pain modalities
Number of subjects: 12981

Group type: EXPERIMENTAL
Intervention: Surgery as a cause of chronic pain
Number of subjects: 12981
Study: 21942288

Group type: EXPERIMENTAL
Intervention: Toothbrushing immediately after bleaching
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Toothbrushing 1 hour after bleaching
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Toothbrushing 2 hours after bleaching
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no toothbrushing)
Number of subjects: 80
Study: 19070440

Group type: EXPERIMENTAL
Intervention: 10mg aripiprazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5mg aripiprazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5mg and 10mg aripiprazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17623736

Group type: EXPERIMENTAL
Intervention: IVIG 0.4 g/kg per month
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 16220024

Group type: EXPERIMENTAL
Intervention: Bilateral ECT (6 sessions)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (prior to antidepressive treatment)
Number of subjects: 12
Study: 14578019

Group type: EXPERIMENTAL
Intervention: Apomorphine (0.005 mg/kg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: NaCl (placebo)
Number of subjects: 64
Study: 9923795

Group type: EXPERIMENTAL
Intervention: Exogenous insulin (n = 8)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standard care (n = 5)
Number of subjects: 13
Study: 7538682

Group type: EXPERIMENTAL
Intervention: Polyurethane-covered self-expanding metallic endoprosthesis
Number of subjects: 32
Study: 2103755

Group type: EXPERIMENTAL
Intervention: Micronutrient antioxidant therapy (daily doses of 600 micrograms organic selenium, 9000 IU beta carotene, 0.54 g vitamin C, 270 IU vitamin E, and 2 g methionine)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Micronutrient antioxidant therapy
Number of subjects: 28
Study: 6990476

Group type: EXPERIMENTAL
Intervention: 25 degrees 'jack-knife' position
Number of subjects: 78

Group type: COMPARATOR
Intervention: 45 degrees 'jack-knife' position
Number of subjects: 78
Study: 29490041

Group type: EXPERIMENTAL
Intervention: Solution-focused wellness intervention (seven-week duration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 27080156

Group type: EXPERIMENTAL
Intervention: Basic diagnostic scoring instrument
Number of subjects: 7262

Group type: EXPERIMENTAL
Intervention: Enhanced diagnostic scoring instrument
Number of subjects: 7262
Study: 24582799

Group type: EXPERIMENTAL
Intervention: Calcium lactate pre-rinse (CaL, 150mmol/L, 1min) followed by fluoride rinse (NaF 12mmol/L, 1min)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fluoride rinse only (NaF 12mmol/L, 1min)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No rinse (negative control)
Number of subjects: 15
Study: 22257577

Group type: EXPERIMENTAL
Intervention: NVA237 (glycopyrronium bromide) at doses of 25, 50, 100, or 200 μg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20417567

Group type: EXPERIMENTAL
Intervention: DEX implant 0.7 mg
Number of subjects: 1267

Group type: EXPERIMENTAL
Intervention: DEX implant 0.35 mg
Number of subjects: 1267

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 1267
Study: 18703600

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation for relief of angina
Number of subjects: 23
Study: 15797163

Group type: EXPERIMENTAL
Intervention: Telephone-delivered, self-efficacy based intervention (6 sessions every 2 weeks)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Telephone-delivered, self-efficacy based intervention
Number of subjects: 65
Study: 12876902

Group type: EXPERIMENTAL
Intervention: Inactivated split‐virion (Imovax Gripe)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Sub‐unit (Agrippal S1)
Number of subjects: 344
Study: 10379328

Group type: EXPERIMENTAL
Intervention: Prophylactic fixation with intramedullary nailing
Number of subjects: 24

Group type: COMPARATOR
Intervention: Prophylactic fixation with dynamic compression plating
Number of subjects: 24

Group type: COMPARATOR
Intervention: Prophylactic fixation with Rush rodding
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prophylactic fixation with locked intramedullary nailing
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intact humeri
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Humeri with a 50% hemicylindrical cortical central 1/3 defect
Number of subjects: 24
Study: 8707580

Group type: EXPERIMENTAL
Intervention: Dimethindene maleate (Fenistil gel)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Optiderm
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Xylocaine‐Salbe 5%
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo cream corresponding to Optiderm
Number of subjects: 12
Study: 2050319

Group type: EXPERIMENTAL
Intervention: 10 MU of interferon-alpha 2b/m2 body surface area three times a week (group I)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 5 MU of interferon-alpha 2b/m2 body surface area three times a week (group II)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (group III)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Interferon-alpha treatment
Number of subjects: 36
Study: 6197081

Group type: EXPERIMENTAL
Intervention: Radiotherapy to the primary site followed by 10 pulses of chemotherapy (cyclophosphamide, methotrexate, CCNU)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Two pulses of chemotherapy (cyclophosphamide, methotrexate, CCNU) followed by radiotherapy and then 8 pulses of chemotherapy
Number of subjects: 186
Study: 30219959

Group type: EXPERIMENTAL
Intervention: English text
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: English text with pictorial illustrations
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Graphic novel
Number of subjects: 51

Group type: COMPARATOR
Intervention: Within-subject comparison
Number of subjects: 51
Study: 29331975

Group type: EXPERIMENTAL
Intervention: Postoperative orthosis for 6 weeks followed by 6 weeks of weaning
Number of subjects: 46

Group type: COMPARATOR
Intervention: No postoperative orthosis
Number of subjects: 46
Study: 26986091

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 25428213

Group type: EXPERIMENTAL
Intervention: Active intervention (lifestyle intervention)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Standard obstetric care (control)
Number of subjects: 425
Study: 22810146

Group type: EXPERIMENTAL
Intervention: CMV serostatus (measured by CMV IgG antibodies)
Number of subjects: 1230

Group type: COMPARATOR
Intervention: Control group (men not diagnosed with PCa)
Number of subjects: 1230
Study: 20216555

Group type: EXPERIMENTAL
Intervention: Active FM (fermented milk containing Lactobacillus gasseri SBT2055), n=43, 200 g/day for 12 weeks
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control FM (fermented milk without Lactobacillus gasseri SBT2055), n=44, 200 g/day for 12 weeks
Number of subjects: 87
Study: 17505679

Group type: EXPERIMENTAL
Intervention: Active TEA (15 ml 0.5% bupivacaine)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (15 ml 0.9% saline)
Number of subjects: 19
Study: 15322696

Group type: EXPERIMENTAL
Intervention: SSRI+GC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SSRI+CBT
Number of subjects: 0

Group type: COMPARATOR
Intervention: PL+GC
Number of subjects: 0

Group type: COMPARATOR
Intervention: PL+CBT
Number of subjects: 0
Study: 11914400

Group type: EXPERIMENTAL
Intervention: Patients with PPMS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study: 9802851

Group type: COMPARATOR
Intervention: SCD
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: SCD/enoxaparin
Number of subjects: 68
Study: 8533119

Group type: EXPERIMENTAL
Intervention: Phenytoin 100 mg/day, 200 mg/day, or 300 mg/day for 14 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 2689261

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 1101478

Group type: EXPERIMENTAL
Intervention: Horse antihuman thymocyte globulin (ATG) with azathioprine and prednisone
Number of subjects: 2

Group type: COMPARATOR
Intervention: Azathioprine and prednisone alone
Number of subjects: 2
Study: 31283908

Group type: EXPERIMENTAL
Intervention: nabilone (0.5 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: nicotine (6 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: nicotine (6 mg) + nabilone (0.5 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 28094198

Group type: EXPERIMENTAL
Intervention: APBI with interstitial brachytherapy
Number of subjects: 1184

Group type: COMPARATOR
Intervention: Whole-breast irradiation
Number of subjects: 1184
Study: 26334853

Group type: EXPERIMENTAL
Intervention: Red blood cells (RBC) transfusion during ECC
Number of subjects: 30

Group type: COMPARATOR
Intervention: No RBC transfusion during ECC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (RBC transfusion and no transfusion)
Number of subjects: 30
Study: 23004922

Group type: EXPERIMENTAL
Intervention: Low-dose ASA (100 mg/d) ingested 8 hours after awakening
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Low-dose ASA (100 mg/d) ingested at bedtime
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Low-dose ASA (100 mg/d) ingested upon awakening
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Low-dose ASA (100 mg/d)
Number of subjects: 350
Study: 16856895

Group type: EXPERIMENTAL
Intervention: Laser excision
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional gingivectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Flap surgery
Number of subjects: 50
Study: 12647193

Group type: EXPERIMENTAL
Intervention: High frequency ventilation (HFV)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 300
Study: 10929272

Group type: EXPERIMENTAL
Intervention: Corticosteroids or adrenocorticotropic hormone (ACTH) treatment
Number of subjects: 1714

Group type: EXPERIMENTAL
Intervention: Corticosteroids or ACTH treatment
Number of subjects: 1714
Study: 8799525

Group type: EXPERIMENTAL
Intervention: Ketoprofen 12.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1344236

Group type: EXPERIMENTAL
Intervention: Intramuscular meperidine 25mg IM
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% N/S 0.5ml IM (Control)
Number of subjects: 60
Study: 6424464

Group type: EXPERIMENTAL
Intervention: Oral nonabsorbable antibiotics and isolation in laminar airflow room (36 patients)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Prophylactic granulocyte transfusions from a single family member donor (33 patients)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conventional treatment in single rooms with hand-washing and mask precautions (31 patients)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Laminar airflow room (36 patients)
Number of subjects: 101
Study: 31730539

Group type: EXPERIMENTAL
Intervention: Aromatherapy with lavender essential oil
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Aromatherapy with Damask rose essential oil
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 90
Study: 31445838

Group type: EXPERIMENTAL
Intervention: StrataXRT®
Number of subjects: 197

Group type: COMPARATOR
Intervention: Sorbolene (10% Glycerine)
Number of subjects: 197
Study: 27995837

Group type: EXPERIMENTAL
Intervention: Conventional 4% chlorhexidine scrub
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Waterless hand rub (1% chlorhexidine gluconate and 61% ethyl alcohol)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Conventional 10% povidone‐iodine scrub
Number of subjects: 240
Study: 25767380

Group type: EXPERIMENTAL
Intervention: Resistance training (RT) performed three times per week (G3x)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Resistance training (RT) performed two times per week (G2x)
Number of subjects: 53
Study: 24040974

Group type: EXPERIMENTAL
Intervention: Unpleasant odor probe
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pleasant odor probe
Number of subjects: 18

Group type: COMPARATOR
Intervention: Neutral odor
Number of subjects: 18
Study: 20969725

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 20017349

Group type: EXPERIMENTAL
Intervention: N-acetylcholine nephroprotector during CAG
Number of subjects: 36

Group type: COMPARATOR
Intervention: CAG without nephroprotection
Number of subjects: 36
Study: 17347567

Group type: EXPERIMENTAL
Intervention: Individualized 8-week training program of mobility and toileting skills
Number of subjects: 57

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 57
Study: 15547093

Group type: EXPERIMENTAL
Intervention: Infliximab treatment (5 mg/kg)
Number of subjects: 49
Study: 11560099

Group type: EXPERIMENTAL
Intervention: EE20/GSD75
Number of subjects: 216
Study: 9747153

Group type: EXPERIMENTAL
Intervention: rt-PA (20 mg administered locoregionally over 4 hours for a maximum of 7 days)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: urokinase (100,000 IU/h administered locoregionally for a maximum of 7 days)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (intravenous heparin infusions after PTT)
Number of subjects: 69
Study: 7831457

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 25
Study: 2467608

Group type: EXPERIMENTAL
Intervention: Cefotaxime (CTX)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard therapy (ST) - penicillin-chloramphenicol combination with or without sulphadiazine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard therapy (ST)
Number of subjects: 31
Study: 31586206

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13) during maintenance chemotherapy (Group 1)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13) at end of chemotherapy (Group 2)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13) 6 months after chemotherapy (Group 3)
Number of subjects: 118
Study: 28292331

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for depression, 16-20 sessions
Number of subjects: 104

Group type: COMPARATOR
Intervention: Short-term psychodynamic psychotherapy for depression, 16-20 sessions
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Short-term psychodynamic psychotherapy for depression
Number of subjects: 104
Study: 26430087

Group type: EXPERIMENTAL
Intervention: APOL1 high-risk genotype
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Obesity (BMI ≥ 30 kg/m(2))
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Increased urinary excretion of urea nitrogen (≥ 8 g/d)
Number of subjects: 693
Study: 23428922

Group type: EXPERIMENTAL
Intervention: Rosuvastatin treatment
Number of subjects: 314

Group type: COMPARATOR
Intervention: Pravastatin treatment
Number of subjects: 314
Study: 21481998

Group type: EXPERIMENTAL
Intervention: Implicit task with self-selected actions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Incompatible spatial training
Number of subjects: 0
Study: 19222545

Group type: EXPERIMENTAL
Intervention: Pregabalin (PGB)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 178
Study: 16862612

Group type: EXPERIMENTAL
Intervention: TEP laparoscopic patch repair
Number of subjects: 1513

Group type: COMPARATOR
Intervention: Lichtenstein mesh technique
Number of subjects: 1513
Study: 15476991

Group type: EXPERIMENTAL
Intervention: Community rehabilitation service (CRN) including orientation meeting, self-help course, stress management program, water exercises class, informal social and recreational activities.
Number of subjects: 29

Group type: COMPARATOR
Intervention: Comparison group (no specific intervention details provided).
Number of subjects: 29
Study: 10679609

Group type: EXPERIMENTAL
Intervention: Life albums created by residents
Number of subjects: 13